Celcuity gains as breast cancer drug launches in US

Pfizer

30/09/2026 14:19

** Shares of drugmaker Celcuity CELC.O rise 4.11% to $80.56 premarket 
** Co says its FDA-approved breast cancer drug Revtorpyk is now commercially available in the US
** Drug is approved with fulvestrant, with or without Pfizer's PFE.N Ibrance, for certain patients with advanced breast cancer whose tumours do not have a PIK3CA gene mutation and whose disease worsened after hormone therapy
** Citizens estimates a one-month supply will cost $30,000 and forecasts Revtorpyk sales of $6.5 million in 2026
** Brokerage maintains its "market outperform" rating and $177 price target, citing the drug's effectiveness and Celcuity's preparations for the launch
** CELC is also seeking FDA approval for Revtorpyk in patients whose tumours have PIK3CA mutations, which could broaden the drug's use
** As of last close, CELC down 22.4% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))